Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The volume on RUM is from another universe! I read the news and it's very nice. I will be doing DD on it. Many thanks for the turn-on. :)
Thanks for letting me know man and GLTY on your next big trade! Will stay in touch.
$2.00's trading :)
Up more After hours. $1.79 showing up 54% at close
I agree with you! Excellent points! Now if the Company can come out with a solid update on the Merck news or of another deal then IMHO the shorts will flee. They don't think any updates are gonna happen.
Up 48% regular hours. that is pretty good. :)
Filled at .35 just before the close of A-H. Hoping for the best on Monday. Have a good weekend :)
Well, the filling is nice and made the shares higher on some nice volume. FOXO is in a hot sector. The question I have is = Are they gonna PR this filing on Monday? Would make for excellent news to start the week and could create a MOMO.
They are very late with their Q and trying to figure out the outstanding is difficult but certainly had dilution.
I did make $$ on this once with a quick in and out but didn't take a position this time. If she dips below .35 tonight then I might buy some. It could do well long term but still need to see what is happening in their financial department. At least the filing says revenue in on the way with their deal
Item 1.01 Entry Into A Material Definitive Agreement.
Effective January 12, 2024, Foxo Technologies Inc., a Delaware corporation (the “Company” or the “Licensee”), entered into the Master Software and Services Agreement (this “Agreement”) with KR8 AI Inc., a Nevada corporation (the “Licensor”). Our Interim CEO and Interim CFO each are equity owners of the Licensor. Under the Agreement, the Licensor granted to the Licensee a limited, non-sublicensable, non-transferable perpetual license to use the “Licensor Products” listed in Exhibit A to the Agreement, to develop, launch and maintain license applications based upon Licensee’s epigenetic biomarker technology and software to develop an AI machine learning epigenetic APP to enhance health, wellness and longevity. The territory of the Agreement is solely within the U.S., Canada and Mexico.
Under the Agreement, the Licensee agreed to pay to the Licensor an initial license and development fee of $2,500,000, a monthly maintenance fee of $50,000, and an ongoing royalty equal to 15% of “Subscriber Revenues,” as defined in the Agreement, in accordance with the terms and subject to the minimums set forth in the schedules of the Agreement. The Licensee agreed to reimburse the Licensor for all reasonable travel and out-of-pocket expenses incurred in connection with the performance of the services under the Agreement, in addition to payment of any applicable hourly rates. If the Licensee fails to timely pay the “Minimum Royalty,” as defined in the Agreement, due with respect to any calendar year, the License will become non-exclusive.
The initial term of this Agreement commences on the effective date of the Agreement. Unless terminated earlier in accordance with the terms, the Agreement will be perpetual. Either party may terminate the Agreement, effective on written notice to the other party, if the other party materially breaches this Agreement, and such breach remains uncured 30 days after the non-breaching party provides the breaching party with written notice of such breach, in which event, the non-breaching party will then deliver a second written notice to the breaching party terminating this Agreement, in which event the Agreement, and the licenses granted under the Agreement, will terminate on the date specified in such second notice. Either party may terminate the Agreement, effective immediately upon written notice to the other party, if the other party: (i) is unable to pay, or fails to pay, its debts as they become due; (ii) becomes insolvent, files or has filed against it, a petition for voluntary or involuntary bankruptcy or otherwise becomes subject, voluntarily or involuntarily, to any proceeding under any domestic or foreign bankruptcy or insolvency law; (iii) makes or seeks to make a general assignment for the benefit of its creditors; or (iv) applies for or has appointed a receiver, trustee, custodian, or similar agent appointed by order of any court of competent jurisdiction to take charge of or sell any material portion of its property or business.
Licensee may terminate the Agreement at any time upon 90 days’ notice to the Licensor provided that, as a condition to such termination, the Licensee immediately ceases using any Licensor Products. The Licensor may terminate the Agreement at any time upon 30 days’ notice to the Licensee if the Licensee fails to pay any portion of the “Initial License Fee,” as defined in the Agreement.
Exactly!!!!!!!
This is how she treats shorts
Thinking next week
Artemisia the shorts killer starts on Monday. She has a fantastic video resume!
Oh, Nice! very nice. A couple of excerps from the DR's letter
we expect our advanced biomaterial products and biobanking businesses to achieve net sales percentage growth in the range of 176.1% to 193.0% for the fourth quarter 2023 compared to the fourth quarter 2022. For the full year 2023, we expect net sales percentage growth in the range of 22.7% to 26.6% compared to the full year 2022.
We anticipate shortly that we will announce our expectations for net sales in the first quarter 2024 and the full year 2024, respectively, reflecting three core focuses:
Recently, we took steps to improve our balance sheet and support the growth of our businesses. On Wednesday, 17 January, we announced the closing of two separate financing transactions in which Celularity received combined total gross proceeds of $21 million from a $6 million private placement transaction with our largest single shareholder and a $15 million loan agreement amendment with an existing lender, respectively.
Anytime bro! Got you marked, :)
They Hire John Powers as the new President and then the CEO buys 1 million dollars worth of stock. If the writing is not on the wall then you can have me committed
Nothing goes straight up, ridges, valleys, potholes, turbulence, and air pockets. Anything under $1.00 is taking candy from a baby
They Hire John Powers as the new President and then the CEO buys 1 million dollars worth of stock. If the writing is not on the wall then you can have me committed
Nothing goes straight up, ridges, valleys, potholes, turbulence, and air pockets. Anything under $1.00 is taking candy from a baby
Check MRAI
Shorts are evil. Now we long have more evil than you can imagine! Watch your asses!
Turn around situation imo
Dunno but with enough buying power we can break wide open imo
If this doesn't get halted I will know its all a sham. Happy you made some cabbage on this :)
If this doesn't get halted I will know its all a sham. Happy you made some cabbage on this :)
Outstanding as of December 21, 2023
Common Stock, $0.001 par value 1,701,243
Agrify’s Enters Into First Hydrocarbon Extraction Lab & Vertical Farming Unit Facility in California
TROY, Mich., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced it has entered into a multi-million dollar sales agreement (“the Agreement”) with Ocean Deep/Golden Lake Business Park, a California-based vertically integrated cannabis operator. Ocean Deep will be extracting products with Agrify’s turnkey PX30 Hydrocarbon Extraction Lab Package to bolster its product offerings. Ocean Deep is also expected to begin operation with an estimated 120 Vertical Farming Units (“VFUs”) sold by the Company to produce high-quality cannabis flower in 2024.
The PX30 Hydrocarbon Extraction System is the largest system of Agrify’s PX-series. The PX30’s four 7.5 lbs. material columns can be run in parallel, allowing a complete 30-pound batch cycle in under 60 minutes, and making it one of the largest and fastest extractors on the market with up to 240+ lbs. per 8-hour shift. This robust system is poised to offer enhanced capabilities for hydrocarbon extraction, catering to the demands of commercial operators focusing on large-scale batch processing and extracting for the creation of direct-to-consumer products.
Raymond Chang, Chairman and CEO of Agrify, shared that “We are very excited to announce this agreement for the sale of our first combined VFU and PX30 Hydrocarbon Extraction Lab facility in the state of California. We applaud our partner Ocean Deep/Golden Lake Business Park’s foresight for selecting Agrify’s technologies in the fiercely competitive California market. We believe our superior cultivation and extraction technologies will allow Ocean Deep to offer the highest quality and most consistent products to its customers.”
The addition of Agrify’s UL-compliant Explosion Proof (EXP) Rooms was, the Company believes, an ideal choice for Ocean Deep’s C1D1 extraction lab. Agrify’s safe and easy to install C1D1/C1D2 extraction rooms are designed to be easily set up in less than one day and are equipped with a PSI technical report certification for professional engineers to field verify in all 50 states.
“As CEO of Ocean Deep/Golden Lake Business Park, it is with great enthusiasm that I disclose our new alliance with Agrify, renowned for their trailblazing cannabis cultivation and extraction innovations. Our southern California operations will proudly serve as a showcase for their end-to-end cannabis solutions,” said Mr. Sun, CEO of Ocean Deep/Golden Lake Business Park. “We chose Agrify because their approach to the industry is grounded in science and focuses on efficiency which resonate with our mission to redefine industry benchmarks through the adoption of forefront technologies that amplify our production capabilities and assure superior product quality. We look forward to the advancements and triumphs that our combined efforts will yield.”
These industry developments illustrate the continuous innovation and commitment to safety within the cannabis sector as Agrify adapts to expanding market demands.
LMFAO! That is hilarious!
Insider buys 21.4 mil shares @ $0.249 https://www.otcmarkets.com/filing/html?id=17188617&guid=9qJ-kH0-h3zG-hh
1.1 mil shares! Even better. :)
Insider bought 1 mil shares https://www.otcmarkets.com/filing/html?id=17187667&guid=FeJ-kKydxzxPB3h
OMG, now I know we entered a different universe! How the hell are you MR Doog?
MIMO - might experience a distortion of spacetime, potentially leading to time dilation, gravitational forces, and other phenomena.
LMAO! As of November 3, 2023, 74,638,893 shares of the registrant’s common stock, par value $0.0001 per share, were issued and outstanding.
Were heading to a different universe! :)
Hey Zorro buddy! :)
I dunno brother but it's gonna be a very interesting open as it already traded its entire shares outstanding
Shorts are smacking us!
INSANITY!
Up 100% A.H no news?
Very nice News! Applied UV Inc. Announces Launch of Patented Fighter Flex LED Solution Opening Significant Revenue Opportunity
DENVER, CO, Jan. 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Applied UV Inc. (NASDAQ: AUVI), a leader in smart building technology solutions, is excited to announce the launch of its groundbreaking Fighter Flex LED solution at the upcoming AHR Expo on January 22nd. This disruptive technology is set to redefine energy efficiency in heating, ventilation, and air conditioning (HVAC) systems across the industry. Applied UV Inc. is finalizing distribution agreements with several major international smart building technology brands. The Fighter Flex LED technology was selected by the GSA and DOE for the GSA Green Proving Ground Program.
Max Munn, CEO of Applied UV, stated, 'We are delighted about the immense potential with this opportunity.” Munn remarked, “Given the disruptive technology in our patented Fighter Flex LED products, we are confident in our ability to capture a significant share of this market. We believe this market holds an annual sales opportunity in the hundreds of millions of dollars."
Efficiency Gains from UV and Next Gen LED
In the United States, office spaces typically require between 50,000 to 75,000 BTUs per year per square foot for heating, influenced by factors such as building age, insulation quality, and local climate. For a standard office building in a moderate climate, air conditioning costs alone can reach approximately $2-$3 per square foot annually.
Utilizing our patented UVC LED system to maintain the efficiency of HVAC coils has proven to reduce energy consumption by 5-15%. For an owner of a 100,000 square foot office space, the integration of UVC technology could equate to approximately $45,000 in energy savings in the first year alone.
The LED Revolution in HVAC Systems
Applied UV Inc.'s patented UVC LED fixtures offer a refined alternative to traditional mercury vapor UVC bulbs. Our state-of-the-art fixtures deliver targeted UVC illumination, avoiding wastage on non-essential surfaces, and provide precise dosing control. The switch to UVC LED fixtures from mercury vapor tubes (a 100-year-old technology) can result in an additional 100% increase in energy savings within the UV system, leading to on average an additional $10,000 in annual savings for a 100,000 square foot property.
Sustainability Meets Innovation
The Fighter Flex LED solution boasts durable, low-maintenance, and mercury-free emitters, marking a significant advancement in UVC LED technology. Applied UV Inc.’s commitment to innovation has been recognized with a major federal agency initiating a full trial of their patent-pending UVC LED design, signifying a transformative step in UV application for coil cleaning within building HVAC systems.
About Applied UV Inc.
NEWS
Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries
DALLAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASD:MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, announces the enrollment of the first patient in the pivotal study to validate DeepView AI® using its proprietary imaging technology for burn size and healing assessment. This pivotal study is expected to be the final clinical trial before seeking FDA marketing authorization for the burn indication in 2025 and will be conducted in burn centers and emergency departments across the US, enrolling both adults and pediatric patients.
Niko Pagoulatos, Ph.D., Chief Operating Officer of the Company stated: “We believe this study will further demonstrate the truly innovative and versatile nature of our technology, as well as its ability to predict burn wound healing potential on the first day of injury with significantly greater accuracy and speed than the methods currently used today. We continue to utilize $251 million of non-dilutive government funding since 2019 to validate DeepView for burn indication, while aggressively advancing other clinical indications like diabetic foot ulcers in pursuit of our ‘one platform—multiple clinical indications’ strategy.”
“We are excited to begin enrollment in this pivotal study implementing the DeepView system in clinical sites across the United States. The study will help us validate DeepView’s game-changing AI to accurately assess burn wound healing potential on day-one which could lead to early treatment decisions,” said Jeffrey C. Carter, MD, FACS, the lead investigator for the study. “This study is anticipated to deepen the knowledge and understanding of how DeepView will transform burn care pathways while improving patient outcomes, concurrently strengthening our country against the challenges of Burn Mass Casualty Incidents to safeguard and prepare for unforeseen emergencies.”
The data obtained in the study will be compared to assessment by physicians and used for regulatory submission to the FDA by the first half of 2025. Further details of the study can be found at clinicaltrials.gov.
This project is being supported in whole or in part with federal funds from the Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C00049. The findings and conclusions have not been formally disseminated by HHS and should not be construed to represent any agency determination or policy.
About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView system. DeepView is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
Forward Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.
Contacts:
Investors: